Targets › PRLR
1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Jul 2028.
This is a receptor for the anterior pituitary hormone prolactin (PRL). Acts as a prosurvival factor for spermatozoa by inhibiting sperm capacitation through suppression of SRC kinase activation and stimulation of AKT. Isoform 4 is unable to transduce prolactin signaling. (UniProt, P16471)
Open in Phaseline: the race on PRLR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Absci | ABS-201 IgG1 monoclonal antibody targeting prolactin receptor (PRLR) | PRLR | Phase 1 | Androgenetic Alopecia (AGA) | Jul 2028 |
Androgenetic Alopecia (AGA) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.